



SERSTECH GROUP — YEAR END REPORT 2022

SERSTECH GROUP FOURTH QUARTER 2022

- Net sales amounted to KSEK 3 488 (2 910).
- Net earnings for the period: KSEK -16 229 (-2 894).
- One-off write-down of capitalized development costs: KSEK 7 451 (1 058).
- Earnings per share: SEK -0.19 (-0.03).
- Earnings per average number of shares: SEK -0.19 (-0.03).
- Investment in equipment: KSEK 17 (47).
- Investment in intangible assets: KSEK 1 578 (4 036).
- Cash and cash equivalents: KSEK 1 866 (19 574).
- Equity ratio (%): 51% (84%).

SERSTECH GROUP FULL YEAR 2022

- Net sales: KSEK 17 112 (18 650).
- Net earnings for the period: KSEK -29 566 (-10 251).
- One-off write-down of capitalized development costs: KSEK 10 593 (3 030).
- Earnings per share: SEK -0.35 (-0.12).
- Earnings per average number of shares: SEK -0.35 (-0.13).
- Investment in equipment: KSEK 30 (278).
- Investment in intangible assets: KSEK 7 560 (12 284).
- Cash and cash equivalents: KSEK 1 866 (19 574).
- Equity ratio (%): 51% (84%).

MESSAGE FROM THE CEO

At the end of 2021, the sales pipeline started to grow rather dramatically, more than doubling its size in December alone. Since then, the pipeline has continued to grow, which is a clear indication that the market is waking up again, after 30 months of pandemic slumber. In our line of business, the time from a customer is ready to buy until they actually buy is typically one year. As was communicated in December 2022, we received an order of 10 MSEK from a partner in Singapore at the end of the year. The large order, which is one of the largest so far, was also the first order from South-East Asia since before the pandemic. South-East Asia has historically been our strongest sales region, and we expect to see good contributions from this region in 2023 and onwards as the customers resume normal operations.



An order of 10 MSEK from a partner in Singapore, which is one of the largest so far, was also the first order from South-East Asia since before the pandemic.'

— Stefan Sandor, Serstech CEO.

The pandemic period, which in the sales context included most of 2022, has had Serstech focused on reducing cost, in combination with preparations for the return of the market. The Serstech team was reduced by 15 people during the pandemic, and during the fourth quarter of 2022, we finally started to recruit again. With a continued growth in our sales pipeline and with multiple opportunities expected to close during the first half of 2023, we are strengthening our capacity in R&D, sales and technical support. Already at the beginning of February 2023, our sales had surpassed 60% of the 2022 full-year sales.

To ensure that we are ready to meet the demand we saw building in 2022, we performed a rights issue in Q4 and added approximately 20 MSEK to our cash balance in January 2023. Out of the 108 rights issues that were made in 2022 on Nasdaq First North, ours had the third highest subscription rate with 152%, which shows that our shareholders share our optimism for 2023 and onwards. The order of 10 MSEK received at the end of December will be invoiced in February, which will bring our cash balance to the highest level ever.

Our new sales director for Europe has done an excellent job during the year. We have added several strong sales partners and the sales pipeline in Europe has continued to grow significantly. One of the drivers in Europe is the increased demand for solutions that can identify chemical warfare agents. As in the rest or the world, the post-pandemic resumed focus on drug enforcement by police and border control, has increased the demand in our core business segment. We therefore expect the European sales region to perform very well in 2023.

We had our first major order from the US market in May 2022. The order value was more than 8 MSEK and it was delivered during the summer to a state prison authority, which has deployed Serstech instruments in all prisons throughout the state. The feedback from the customer is positive and we have received requests for information from other prison systems in the country, and we expect the importance of the US market to continue to grow over the coming years.

Most of our competitors are from the US, and many customers have a preference to buy from domestic manufacturers. This is one of the main reasons why it has taken Serstech almost three years to get the first major order. We now have a good local reference, and we have thereby passed a great hurdle in the sales development. In 2022, we added our second salesperson in the country, and we will continue to strengthen our sales capacity in 2023 and 2024.

Early 2022, we cancelled our OEM agreements with Environics and Field Forensics. Field Forensics remains one of our most valued partners, and they are now selling our products under the Serstech brand. The main reason for entering into the OEM agreements in 2018 and 2019 was to get access to established sales networks of more experienced companies, since we did not have our own sales channel yet. As we now have a strong partner network, we instead focus on continuing to build our sales and brand through our own channels, and to improve our gross margins.

The global component shortage has been one of the challenges throughout 2022. We have however succeeded in building the necessary component inventory, even if it has meant several electronics redesigns during the year. Many component suppliers stopped producing less profitable components during the year and focused on their latest generations only, which forced us to upgrade several critical components on our circuit boards. The positive side-effects of changing to the latest generation components include noticeably faster instruments and lower battery consumption. During the development work, we also managed to reduce the number and cost of components.

While the net sales in 2022 were severely affected by the pandemic, everything aligned perfectly for imminently resumed growth. The pent-up demand created by the absence of sales in the market for 30 months, the resumed focus on drug enforcement and the demand created by the risk of chemical warfare in Europe combine to drive up total demand to unprecedented levels. At the same time, we have a strong cash balance from the successful rights issue and the resumed sales. Our next-generation product Serstech Arx is in volume production since Q4 2022, and we have sufficient component inventory for at least the first quarters of 2023. We expect and predict strong or very strong growth in 2023 and onwards.

Stefan Sandor, CEO February 2023





Internal and external factors have aligned perfectly over the last 12 months, and everything is in place for imminent return to growth. Already in early February, we had reached more than 60% of the 2022 full-year sales.'

— Stefan Sandor, Serstech CEO.



SIGNIFICANT EVENTS DURING THE PERIOD

RIGHTS ISSUING OF NEW SHARES TO SECURE FURTHER MARKET INVESTMENTS.

The Board's resolved, on behalf of the Extra Annual Shareholders meeting on December 9, 2022, to carry out a rights issue with preferential rights for existing shareholders, amounting approximately 23 MSEK before issue costs. The rights issue was carried out and closed in January 2023.

The issue is carried out to secure delivery capacity to known business opportunities as well as further investment in sales.

CLOSED NEW ORDER OF 10 MSEK FROM SINGAPORE.

Serstech signed a new order of 10 MSEK from its partner Kaiser-SGI in Singapore. The order contains the newest-generation Serstech Arx, the patented SERS kit and Serstech ChemDash software. The order was invoiced in December 2022 and will be delivered in the first quarter of 2023.

DEDUCTED CAPITALIZED WORK FOR OWN ACCOUNT.

In connection with year-end closing 2022, a one-off write-down of capitalized development costs, amounting to 10.6 MSEK, has been made. The amount includes depreciations made during 2022. The one-off write-down relates to technology that no longer will be used in the company's products and has been phased out.

SHORT-TIME ALLOWANCE PAID OUT BY TILLVÄXTVERKET.

In connection with year-end closing 2022, accruals have been made to cover already decided and by Tillväxtverket paid out short-time allowance. New decision has been served by Tillväxtverket and the new decision has been appealed by Serstech.

SIGNIFICANT EVENTS AFTER THE PERIOD

RIGHTS ISSUING WAS SUBSCRIBED TO 152% AND AN OVER-ALLOTMENT ISSUE WAS CARRIED OUT.

The rights issue in Serstech AB (publ) was subscribed to 152 percent and the warranty agreements entered will therefore not be used. As a result of the high subscription rate, an over-allotment issue of approximately 1.1 million was carried out. Through the two issues, the Company receives a total of approximately SEK 24.6 million before deductions for issue costs.

ABOUT SERSTECH

Serstech develops and markets optical instruments and software that are used by law enforcement, border control and first responders to identify dangerous or hazardous chemicals. Each instrument contains a Raman spectrometer, which is used to analyze the optical fingerprint of more than 17 000 different chemicals, such as narcotics, explosives, toxic industrial chemicals, and chemical warfare agents. Since the instruments emit and receive optical signals, the chemicals of interest can often be analyzed through packaging materials. By not opening the packaging, the operator is not exposed to the dangerous chemicals inside, and the potential evidence is not affected or consumed by the analysis.

Serstech entered its commercial phase in 2018 and has since built a sales channel that spans the globe. Serstech today has sales partners in 63 countries and its own sales representatives in five countries and serves customers on all continents. The main competitive advantages of Serstech's products are their usability, speed, small size, low weight, and best-in-class price/performance ratio.

The customer groups are almost exclusively public organizations such as police, bomb squads, HazMat teams (Hazardous Materials), fire departments and border control organizations. Due to the nature of the customers, almost all sales are through public tenders. Local presence through the sales partner network is of essence, since many of the tenders are classified and well-established local connections and relationships are necessary to gain access to them. The sales cycles are long, and the time from first customer contact to first sale is almost always several years.

Research and development is done at sites in Sweden and Romania, all production is in Sweden and the head office is in Lund, Sweden. Having both R&D and production in Sweden is often a distinct advantage, since customers in the security sector are very conscious about the origin of the technologies they deploy. Serstech is the only company in the European Union developing and manufacturing handheld Raman instruments.





PRODUCTS



SERSTECH ARX

Serstech Arx is a revolutionizing instrument, introducing SharpEyeTM – a patented autofocus technology which improves the signal quality dramatically. By detecting the container material and thickness, the focus point can be placed precisely and the content can be identified with minimum interference from the container. The result is a precise identification of the sample, regardless of how it is packaged.



SERSTECH 100 INDICATOR

The Serstech 100 Indicator is a hand-held, small and light Raman spectrometer that can identify more than 14.000 substances. Customisable with fully validated and data-enriched libraries, Serstech 100 Indicator display is easy to understand and gives accurate responses in seconds. Connect it wirelessly or via cable to ChemDash for reporting and management of users, measurements and libraries.



SERSTECH SERS-KIT

The Serstech SERS kit is used together with Serstech Arx or Serstech 100 Indicator to enhance the capability to identify dark coloured substances or mixtures with very low concentrations. The device is capable of detecting very low amounts of "street quality" narcotics samples, including heroin and many fentanyl variants. The Serstech SERS kit is based on patent pending technology used together with disposable SERS surfaces.



SERSTECH CHEMDASH

Serstech's ChemDash software solution allows for integrated management of multiple instruments and libraries. Sharing intelligence in real-time is often essential for police and border control. ChemDash also allows you to quickly and easily update the firmware of all your devices.

ESTABLISHED APPLICATION AREA



NARCOTICS

Customs, police and prison authorities and United Nations are using Serstech's solutions to identify illicit drugs. The database of substances is based on the UN lists of controlled substances and has been produced together with the Swedish Defense Research Agency (FOI) and others.



EXPLOSIVES

Government agencies are the main customer group in this area. The database of substances covers commercially available explosives, improvised explosive devices (IED), home-made explosives and precursors, used in manufacturing of explosives.



HAZARDOUS CHEMICALS

The number of hazardous chemicals is large and growing. Typically, first responders need to quickly and safely identify these chemicals at accident or spill sites. Serstech's database of thousands of hazardous chemicals also includes information that helps the hazmat team to make life-saving decisions on site.



CHEMICAL WARFARE AGENTS

In November 2017, Serstech launched the Chemical Warfare Agents database, which has already been sold to several government agencies. The need for identification if such chemicals is growing and we expect this application area to increase in importance.




PHARMACEUTICAL

Serstech's solutions are used to verify incoming goods of pharmaceutical manufacturers. The handheld instrument makes it quick and easy to verify chemicals without contaminating or destroying the sample.

GEOGRAPHICAL COVERAGE PARTNER NETWORK

Business is local and the value of having local representation can never be overestimated. Serstech's partner network spans the globe and today covers the home countries of more than 80% of the world's population and an even larger part of the global security investments.



Algeria
Angola
Argentina
Australia
Australia
Bangladesh
Belgium
Bolivia
Botswana
Brazil
Brunei
Bulgaria

Cambodia
Canada
Chile
China
Croatia
Czech Republic
Denmark
Ecuador
Egypt
France
Germany
Greece

Hong Kong
Hungary
India
Indonesia
Iraq
Ireland
Israel
Italy
Japan
Kazakhstan
Korea
Kuwait

Lithuania
Malaysia
Mauritius
Mexico
Myanmar
New Zealand
Nigeria
Norway
Pakistan
Peru
Philippines
Poland

Portugal
Rwuanda
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
Spain
Sri Lanka
Sudan
Sweden

Sweden
Switzerland
Taiwan
Taiwan
Thailand
Turkey
JAE
Jganda
JK
Jkraine
USA
Vietnam

FINANCIAL COMMENTS, FULL YEAR 2022

NET SALES AND NET EARNINGS

Net sales full year 2022 amounted to KSEK 17 112 (18 650) showed a decrease of 8% compared to full year 2021 last year mainly due to Covid-19 effects. However, clear indications shows that large customer groups now have moved back to normal operations and that they therefore now are more likely to invest in Serstech solutions and equipment.

The overall expenses full year 2022, increased by 57% or KSEK 15 944 compared to 2021, where the main part or KSEK 10 593 relates to a one-off write-down of capitalized development costs, including the one-off-write down and depreciations made during 2022. Furthermore, investments have been made to rebuilding sales resources in major geographic markets now that markets are opening again post Covid pandemic.

The development expenses are reflected in the capitalized work for own account, KSEK 3 615 (3 321).


Net earnings for the period, full year 2022, amounted to KSEK -29 566 (-10 251), earnings per share amounted to SEK -0.35 per share (-0.12), and to earnings per average number of shares, amounted to -0.35 (-0.13).


DEPRECIATION AND AMORTIZATION

Net earnings for full year 2022, has been affected by KSEK 8 033 (6 853) for depreciation of assets, of which KSEK 150 (308) refers to depreciation of equipment, tools, and installations, and KSEK 7 883 (6 545) refers to depreciation of capitalized development costs and patents.


INVESTMENTS

Total investments amounted to KSEK 7 560 (12 284), where KSEK 7 590 (12 555) relates to intangible fixed assets, capitalized expenditure for development work and patent, and KSEK 30 (278) relates to investments in equipment.





Geographical division of Serstech's net sales 2018 - 2022



PERSONNEL

On December 31, 2022, Serstech Group had 22 employees

	TOTAL	Men	Women
Lund, Sweden	13	10	3
Cluj, Romania	9	7	2
Group	22	17	5

LIQUIDITY AND FINANCING

On December 31, 2022, the group had KSEK 1 866 (19 574) in cash and cash equivalents and KSEK 2 000 (1 000) in unutilized overdraft credit. The cashflow during 2022 was negative, KSEK -17 708 (8 178).

By year end 2022, Serstech had long-term interest-bearing liabilities of KSEK 4 000 (0) and short-term interest-bearing liabilities of KSEK 739 (1 699).

EQUITY, SHARE CAPITAL AND NUMBER OF SHARES

As of December 31, 2022, the equity of Serstech Group amounted to KSEK 26 616 (56 110) and the equity ratio amounted to 51 percent (84). The share capital was on December 31, 2022, divided into 83 816 085 shares with a quota value of SEK 0.11 (0.11).

All shares belong to the same series and have the same voting and profit rights in the company.

ACCOUNTING PRINCIPLES

The report has been prepared in accordance with BFNAR2012:1, Annual Report and Consolidated Financial Statements, K3. The company's assets and liabilities are stated at cost or nominal value, respectively, unless otherwise stated. This is a consolidated report that refers to the Serstech Group, which consists of Serstech AB and its subsidiaries Serstech Förvaltning AB and Serstech Development SRL. This report has been subject to review by the company's auditor.



SERSTECH GROUP INCOME STATEMENT

Amounts in KSEK	2022-10-01 2022-12-31	2021-10-01 2021-12-31	2022-01-01 2022-12-31	2021-01-01 2021-12-31	
REVENUE					
Net sales	3 488	2 910	17 112	18 650	
Capitalized work for own account	640	375	3 615	3 321	
Other operating income	189	2 563	1 684	2 308	
Total revenue	4 317	5 848	22 411	24 279	
EXPENSES					
Raw materials and consumables	-2 421	-743	-7 795	-6 442	
Other external costs	-6 142	-2 391	-16 671	-6 813	
Payroll expenses	-2 852	-3 964	-13 739	-14 431	
Depreciation of tangible and intangible assets	-2 994	-1 683	-8 033	-6 853	
Other operating expenses	-6 413	0	-6 413	0	
Exchange gains and losses, net	361	50	963	148	
Total expenses	-20 460	-8 730	-51 688	-34 391	
EBIT	-16 143	-2 882	-29 278	-10 110	
Interest and similar, net	-86	-27	-209	-147	
EBT	-16 229	-2 909	-29 487	-10 257	
Taxes	0	15	-80	6	
Net Earnings	-16 229	-2 894	-29 566	-10 251	

SERSTECH GROUP **BALANCE SHEET — ASSETS**

	2022-12-31	2021-12-31
Amounts in KSEK	2022-12-31	2021-12-31
Intangible assets		
Intangible assets	34 351	41 054
Total intangible assets	34 351	41 054
Total Intangible assets	34 351	41 054
Tangible assets		
Equipment, tools, fixtures		
and fittings	192	337
Total tangible assets	192	337
Financial assets		
Deferred tax assets	69	52
Total financial assets	69	52
Total fixed assets	34 612	41 444
Current assets		
Inventories etc.		
Inventories	1 868	3 008
Total Inventories	1 868	3 008
Total inventories	1 000	3 000
Comment or a simple		
Current receivables		
Accounts receivable - trade	11 478	800
Current tax assets	196	127
Other receivables	1 707	1 145
Prepaid expenses	818	459
and accrued income Total Current receivables	14 200	2 531
iotal Current receivables	14 200	2 531
	4.077	40.574
Cash and bank balances	1 866	19 574
Tabel comment and the	47.024	25 444
Total current assets	17 934	25 114
TOTAL ACCETS	F0 F44	// 550
TOTAL ASSETS	52 546	66 558

SERSTECH GROUP BALANCE SHEET — EQUITY AND LIABILITIES

	2022-12-31	2021-12-31	
Amounts in KSEK			
Equity			
Equity	26 616	56 110	
Total equity	26 616	56 110	
Provisions	216	118	
Total provision	216	118	
Non-current liabilities			
Liabilities to credit institutions	4 000	0	
Total non-current liabilities	4 000	0	
Current liabilities			
Liabilities to credit institutions	739	1 699	
Advance payment from customers	10 064	66	
Accounts payable	4 957	3 759	
Current tax liabilities	195	311	
Other current liabilities	464	610	
Accrued expenses and deferred income	5 295	3 885	
Total current liabilities	21 714	10 330	
TOTAL EQUITY AND LIABILITIES	52 546	66 558	

SERSTECH GROUP CHANGE IN EQUITY

	2022-10-01	2021-10-01	2022-01-01	2021-01-01	2021-01-01
Amounts in KSEK	2022-12-31	2021-12-31	2022-12-31	2021-12-31	2021-12-31
Equity brought forward	42 858	59 002	56 110	43 872	43 872
Rights issue	0	0	0	24 516	24 516
Issue costs	0	0	0	-2 035	-2 035
Translation difference on consolidation	-13	2	72	8	8
Profit/loss for the period	-16 229	-2 894	-29 566	-10 251	-10 251
Amount at end of period	26 616	56 110	26 616	56 110	56 110

SERSTECH GROUP CASH FLOW ANALYSIS

Amounts in KSEK	2022-10-01 2022-12-31	2021-10-01 2021-12-31	2022-01-01 2022-12-31	2021-01-01 2021-12-31	2021-01-01 2021-12-31
OPERATING ACTIVITIES	2022-12-31	2021-12-31	2022-12-31	2021-12-31	2021-12-31
	1/ 1/2	-2 882	20.270	10 110	10 110
Operating profit	-16 143		-29 278	-10 110	-10 110
Adjustment for items not included in cash flow	9 505 -86	1 677 -27	14 537 -209	6 824 -147	6 824
Interest paid CASHFLOW FROM OPERATING ACTIVITIES	-00	-27	-209	-14/	-147
BEFORE CHANGES TO WORKING CAPITAL	-6 724	-1 232	-14 950	-3 433	-3 433
before changes to working cartial	-0 /24	-1 232	-14 950	-3 433	-3 433
CASHFLOW FROM CHANGES					
IN OPERATING PROFIT					
increase (-)/decrease (+) inventory	327	639	1 140	-813	-813
increase (-)/decrease (+) account receivables	1 599	-92	-614	2 818	2 818
increase (-)/decrease (+) other short-term receivables	-642	-177	-989	1 605	1 605
increase (+)/decrease (-) account payables	2 139	3 003	1 198	-226	-226
increase (+)/decrease (-) other short-term liabilities	1 910	467	1 057	-579	-579
CASHFLOW FROM OPERATING ACTIVITIES	-1 391	2 608	-13 158	-628	-628
INVESTMENT ACTIVITIES					
Acquisition of property, plant and equipment	-17	-47	-30	-278	-278
Sale of property, plant and equipment	0	0	0	7	7
Acquisition of intangible fixed assets	-1 578	-4 036	-7 560	-12 284	-12 284
CASHFLOW FROM INVESTMENT ACTIVITIES	-1 595	-4 083	-7 590	-12 555	-12 555
FINANCING ACTIVITIES	001				
Loans	-286	-4	3 040	-1 120	-1 120
Share issue costs paid	0	0	0	-2 035	-2 035
Rights issue	0	0	0	24 516	24 516
CASHFLOW FROM FINANCING ACTIVITIES	-286	-4	3 040	21 361	21 361
CASHFLOW FOR THIS PERIOD	-3 272	-1 479	-17 708	8 178	8 178
Cash and cash equivalents at beginning of period	5 138	21 053	19 574	11 396	11 396
Cash and cash equivalents at end of period	1 866	19 574	1 866	19 574	19 574

SERSTECH GROUP KEY FIGURES

	2022-10-01	2021-10-01	2022-01-01	2021-01-01
Amounts in KSEK	2022-12-31	2021-12-31	2022-12-31	2021-12-31
PROFITABILITY AND RETURN				
Revenue change (%)	20%	-51%	-8%	-9%
Operating margin (%)	neg	neg	neg	neg
Profit margin (%)	neg	neg	neg	neg
Return on equity (%)	neg	neg	neg	neg
CAPITAL STRUCTURE				
Equity	26 616	56 110	26 616	56 110
Balance sheet	52 546	66 558	52 546	66 558
Capital employed	31 355	57 809	31 355	57 809
Interest-bearing net debt	2 873	-17 875	2 873	-17 875
Capital turnover rate (times)	0,06	0,04	0,29	0,30
Equity ratio (%)	51%	84%	51%	84%
Gearing ratio (%)	18%	3%	18%	3%
Interest coverage	neg	neg	neg	neg
CASH FLOW AND LIQUIDITY				
Cash flow before investments	-1 391	2 608	-13 158	-628
Cash flow after investments	-2 986	-1 475	-20 748	-13 183
Liquid funds	1 866	19 574	1 866	19 574
INVESTMENTS				
Acquisition of property, plant and equipment	-17	-47	-30	-278
Sale of property, plant and equipment	0	0	0	7
Acquisition of intangible fixed assets	-1 578	-4 036	-7 560	-12 284
PERSONNEL				
Average number of employees	17	27	19	22
Revenue per employee	254	219	1 178	1 104
Number of employees	17	28	17	28
DATA PER SHARE				
Number of shares	83 816 085	83 816 085	83 816 085	83 816 085
Earnings per share (SEK)	-0.19	-0.03	-0.35	-0.12
Equity per share (SEK)	0.32	0.67	0.32	0.67
Average number of shares	83 816 085	83 816 085	83 816 085	77 529 879
Earnings per average number of shares	-0.19	-0.03	-0.35	-0.13
	0.17	0.00	0.00	

SERSTECH AB, PARENT COMPANY **INCOME STATEMENT**

Amounts in KSEK	2022-10-01 2022-12-31	2021-10-01 2021-12-31	2022-01-01 2022-12-31	2021-01-01 2021-12-31	
REVENUE					
Net sales	3 488	2 910	17 112	18 650	
Capitalized work for own account	640	444	1 977	3 475	
Other operating income	189	2 559	1 680	2 291	
Total revenue	4 317	5 913	20 769	24 415	
EXPENSES					
Raw materials and consumables	-2 421	-743	-7 795	-6 442	
Other external costs	-6 836	-3 224	-18 631	-9 739	
Payroll expenses	-2 126	-3 181	-10 597	-11 739	
Depreciation of tangible and intangible assets	-2 984	-1 677	-7 998	-6 842	
Other operating expenses	-6 413	0	-6 413	0	
Exchange gains and losses, net	361	52	963	181	
Total Expenses	-20 419	-8 772	-50 471	-34 581	
EBIT	-16 102	-2 859	-29 702	-10 165	
Interest and similar, net	-86	-27	-209	-147	
ЕВТ	-16 188	-2 886	-29 911	-10 312	
Taxes	0	0	0	0	
Net Earnings	-16 188	-2 886	-29 911	-10 312	

SERSTECH AB, PARENT COMPANY **BALANCE SHEET — ASSETS**

Amounts in KSEK	2022-12-31	2021-12-31	
Intangible assets	34 685	41 299	
Intangible assets	34 685		
Total intangible assets	34 005	41 299	
Tomosibile consta			
Tangible assets			
Equipment, tools, fixtures and fittings	116	266	
Total tangible assets	116	266	
3			
Financial assets			
Shares in subsidiaries	143	143	
Total financial assets	143	143	
Total fixed assets	34 944	41 708	
Current assets			
Inventories etc.			
Inventories	1 868	3 008	
Total	1 868	3 008	
Current receivables			
Accounts receivable- trade	11 348	680	
Other receivables from			
Group companies	29	29	
Current tax assets	196	129	
Other receivables	1 496	1 081	
Prepaid expenses	,0		
and accrued income	806	459	
Total Current receivables	13 875	2 378	
		_ = = =	
Cash and bank balances	1 207	19 242	
Cush and Dank Dalances	1 207	17 242	
Total current assets	16 950	24 628	
TOTAL ASSETS	51 894	66 336	

SERSTECH AB, PARENT COMPANY BALANCE SHEET — EQUITY AND LIABILITIES

	2022-12-31	2021-12-31	
Amounts in KSEK			
Equity			
Equity	26 055	55 967	
Total equity	26 055	55 967	
Provisions	216	118	
Total provisions	216	118	
Non-current liabilities			
Liabilities to credit institutions	4 000	0	
Total non-current liabilities	4 000	0	
Current liabilities			
Liabilities to credit institutions	739	1 699	
Advance payment from customers	10 064	66	
Accounts payable	4 957	3 759	
Liabilities to Group companies	245	396	
Other current liabilities	323	446	
Accrued expenses and deferred income	5 295	3 885	
Total current liabilities	21 623	10 251	
TOTAL EQUITY AND LIABILITIES	51 894	66 336	

SERSTECH AB, PARENT COMPANY CHANGE IN EQUITY

Amounts in KSEK	2022-10-01 2022-12-31	2021-10-01 2021-12-31	2022-01-01 2022-12-31	2021-01-01 2021-12-31	2021-01-01 2021-12-31	
Equity brought forward	42 243	58 853	55 967	43 798	43 798	
Rights issue	0	0	0	24 516	24 516	
Issue costs	0	0	0	-2 035	-2 035	
Profit for the period	-16 188	-2 886	-29 911	-10 312	-10 312	
Amount at end of period	26 055	55 967	26 055	55 967	55 967	

SERSTECH AB, PARENT COMPANY **CASH FLOW ANALYSIS**

Amounts in KSEK	2022-10-01 2022-12-31	2021-10-01 2021-12-31	2022-01-01 2022-12-31	2021-01-01 2021-12-31	
OPERATING ACTIVITIES	2022-12-31	2021-12-31	2022-12-31	2021-12-31	
Operating profit	-16 102	-2 859	-29 702	-10 165	
Adjustment for items not included in cash flow	9 495	1 673	14 508	6 833	
Interest paid	-86	-27	-209	-147	
CASHFLOW FROM OPERATING ACTIVITIES					
BEFORE CHANGES TO WORKING CAPITAL	-6 693	-1 213	-15 403	-3 479	
CASHFLOW FROM CHANGES					
IN OPERATING PROFIT					
increase (-)/decrease (+) inventory	327	639	1 140	-813	
increase (-)/decrease (+) account receivables	1 601	-91	-604	2 819	
increase (-)/decrease (+) other short-term receivables	-528	-105	-829	1 669	
increase (+)/decrease (-) account payables	2 139	3 003	1 197	-226	
increase (+)/decrease (-) other short-term liabilities	1 478	404	1 070	-776	
CASHFLOW FROM OPERATING ACTIVITIES	-1 676	2 637	-13 429	-806	
INVESTMENT ACTIVITIES					
Acquisition of property, plant and equipment	0	0	0	-197	
Sale of property, plant and equipment	0	0	0	7	
Acquisition of intangible fixed assets	-1 578	-4 106	-7 646	-12 429	
CASHFLOW FROM INVESTMENT ACTIVITIES	-1 578	-4 106	-7 646	-12 619	
FINANCING ACTIVITIES					
Loans	0	0	3 040	-1 120	
Share issue costs paid	0	0	0	-2 035	
Rights issue	0	0	0	24 516	
CASHFLOW FROM FINANCING ACTIVITIES	0	0	3 040	21 361	
CASH LOW FROM FRANCING ACTIVITIES	O	O	3 040	21 301	
CASHFLOW FOR THIS PERIOD	-3 254	-1 469	-18 035	7 936	
Cash and cash equivalents at beginning of period	4 461	20 711	19 242	11 307	
Cash and cash equivalents at end of period	1 207	19 242	1 207	19 242	

DEFINITIONS

PROFITABILITY AND RETURN

Revenue growth (%) Change in revenue as a percentage of previous period revenue Operating margin (%) Operating profit as a percentage of turnover Profit for the period as a percentage of turnover Profit margin (%) Profit for the period as a percentage of average equity Return on equity (%)

CAPITAL STRUCTURE

Equity (KSEK) Equity at the end of the period

Total assets or total liabilities and equity Balance sheet (KSEK) Capital employed (KSEK) Balance sheet total less non-interest-bearing liabilities, including deferred tax

Net interest-bearing provisions and liabilities less financial assets including liquid Interest-bearing net debt (KSEK)

assets Capital turnover rate (times)

Capital turnover rate (times) Net sales for the year divided by average balance sheet total

Equity as a percentage of total assets Equity ratio (%) Gearing ratio (%) Interest-bearing liabilities divided by equity

Profit after financial items plus financial expenses divided by financial expenses Interest coverage

CASH FLOW AND LIQUIDITY

Liquid funds (KSEK) Bank balances and cash

Cash flow before investments (KSEK) Profit before financial items plus items that do not affect cash flow less change in

working capital

Cash flow after investments (KSEK) Profit after financial items plus items that do not affect cash flow less changes in

working capital and investments

PERSONNEL

Average number of employees Average number of employees during the period Revenue per employee (KSEK) Turnover divided by the average number of employees Number of employees Number of employees at the end of the period

DATA PER SHARE

Number of shares Number of outstanding shares at the end of the period Earnings per share (SEK) Profit for the period divided by the number of shares Equity per share (SEK) Equity divided by the number of shares

Auditor's review

This report has been subject to review by the Company's auditor.

Future reports

The company will provide continuing financial information according to the following schedule:

2023-02-24

Year-end report 2022 (Jan-Dec)

2023-04-27

Quarterly report (Jan-Mar)

2023-04-27

Annual General Meeting

2023-07-14

Half-Year report (Jan-Jun)

2023-11-09

Quarterly report (Jan-Sep)

2024-02-26

Year-end report 2023 (Jan-Dec)

FOR FURTHER INFORMATION, **PLEASE CONTACT:**

Stefan Sandor, CEO, Serstech AB phone: +46 739 606 067 email: ss@serstech.com

Thomas Pileby, Chairman of the Board, Serstech AB

phone: +46 702 072 643 email: tp@serstech.com

Company website: <u>www.serstech.com</u>

Certified advisor to Serstech is Svensk Kapitalmarknadsgranskning AB (SKMG), phone: +46 11 323 07 32, e-mail: ca@skmg.se.

Serstech is traded at Nasdag First North Growth Market and more information about the company can be found at www.serstech.com